Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2022-09-01 00:00:00 ET · period of report 2022-08-31 · accession 0001562180-22-006402 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-01 | 2022-08-31 | AKBA | Burke Steven Keith | SVP, Chief Medical Off | S - Sale | $0.36 | -1,147 | 418.0K | -0.3% | -$412.92 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-31 | S | D | 1,147 | $0.36 | 418,016 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on August 30, 2019. (F2) Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2022, under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. |